Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celularity (CELU) Common Equity (2020 - 2025)

Celularity (CELU) has disclosed Common Equity for 6 consecutive years, with -$20.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Common Equity fell 216.28% to -$20.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$20.1 million, a 216.28% decrease, with the full-year FY2024 number at $8.8 million, down 78.43% from a year prior.
  • Common Equity was -$20.1 million for Q3 2025 at Celularity, up from -$25.5 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $198.9 million in Q4 2022 to a low of -$648.2 million in Q2 2021.
  • A 5-year average of -$4.3 million and a median of $31.2 million in 2024 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: soared 123.16% in 2022, then plummeted 216.28% in 2025.
  • Celularity's Common Equity stood at $99.4 million in 2021, then surged by 100.07% to $198.9 million in 2022, then tumbled by 79.41% to $41.0 million in 2023, then tumbled by 78.43% to $8.8 million in 2024, then plummeted by 327.38% to -$20.1 million in 2025.
  • Per Business Quant, the three most recent readings for CELU's Common Equity are -$20.1 million (Q3 2025), -$25.5 million (Q2 2025), and -$5.5 million (Q1 2025).